ArticleBMC health services research2026
Direct economic burden of 0.9 million hospitalized cancer patients in Shenzhen, China, 2016-2022.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCancer is a prevailing cause of mortality worldwide, imposing an immense economic burden on both individual patients and society at large. Existing studies tend to focus more on the disease burden rather than the economic burden of cancer, failing to fully understand the crucial financial impact on cancer patients.
methodsUsing the data from Electronic Health Records (EHRs) in all hospitals in Shenzhen, we analyzed the direct costs of inpatients with cancer in Shenzhen. The database included 10,540,120 inpatient records during 2016–2022. Furthermore, cancer-related inpatient records were extracted using International Classification of Diseases, 10th Revision. Descriptive statistics were used to analyze demographic variables, the trends of cost-related information during hospitalization, and hospitalization information including length of stay (LOS), number of hospitalized patients, and hospital visits. Additionally, we categorized the hospitalization records into 25 subgroups based on the types of cancer to conduct a more detailed analysis of each subgroup.
resultsDuring 2016 to 2022, 10,540,120 hospitalization records were observed (43.8% were male), of which 886,868 were records of hospitalized cancer patients (46.7% were male). The admissions of cancer patients grew at an average annual rate of 40.74%, while the proportion of total admissions increased from 2.56% in 2016 to 12.97% in 2022. Total hospitalization costs per visit decreased from $4,151.8 in 2016 to $2,925.6 in 2022, out-of-pocket expenses per visit decreased from $1,630.1 in 2016 to $1,086.1 in 2022, all cost estimates were adjusted to constant 2022 US dollars using the Consumer Price Index (CPI). In the analysis of cancer sub-types, lung cancer, liver cancer and stomach cancer were the three cancers with the highest total costs.
conclusionsThe direct medical costs of cancer in Shenzhen presented a trend of increasing inpatient visits and fluctuating medical expenditures, with notable variations by cancer types, patient demographics, and comorbidities. This study highlighted the need for targeted interventions to manage the economic burden on patients and healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.